

FIG. 1

10220471.102501




FIG. 2

10029474-102501




FIG 3

10029171-102501




FIG. 4

10029471-102501




FIG. 5




FIG. 6






FIG. 7

105201" K1102001



Starting Induction Trap vector.



FIGS. 8A and 8B

Figure 9A






Figure 9B (SEQ ID NO: 5)



Protein-Receptor
Interaction

Pathway
Specificity


Activity at disease-
related genetic loci



Pathway
Redundancy

Ligand specific

Overlapping
Pathways



Toxicity






Figure 10


105201-12162001




Figur 11



Figures 12A and 12B





IL-1β NIH3T3 Sentinel Lines



Figures 13A and 13B

105201-12462001



Figures 14A and 14B

SDF-1 and TNF α regulated EL4 Sentinel Lines




Figure 14C

Effect of Celecoxib on IL-1 β
response of NIH3T3 Sentinel Lines




Figure 15

Effect of COX-2 inhibitor Celecoxib on TNF α response of EL-4 Sentinel Lines






Figure 16




MAP kinase Pathway Inhibitors: U0126, PD98059
P38 kinase Inhibitor: SB203580
COX-2 specific inhibitor: NS398, Celecoxib

A. Effect of MEK inhibitor U0126 on IL-1 β response of NIH3T3 Sentinel Lines



B. Effect of cyclosporin A on IL-1 β response of NIH3T3 Sentinel Lines



Figures 18A and 18B